Key Highlights

  • CRSP reported a third quarter 2026 net loss of $111.4 million, or $1.15 per share, versus $106.4 million, or $1.17 per share, a year earlier.
  • Total Revenue was $12.7 million, compared with $0.9 million in the third quarter of 2025.
  • Cash, cash equivalents and marketable securities totaled $2,276.6 million at Sep 30, 2026.
  • Collaboration expense, net, fell to $41.3 million from $57.1 million as the company's share of CASGEVY revenue grew.
  • Nine-month net loss narrowed to $325.5 million from about $451.0 million (calculated) a year earlier.

Third Quarter Loss Widens Slightly as One-Time Revenue Lifts the Top Line

CRISPR Therapeutics (NASDAQ:CRSP) filed its Quarterly Report for the period ended Sep 30, 2026 on Nov 2, 2026. The company recorded a net loss of $111.4 million, or $1.15 per share, compared with a loss of $106.4 million, or $1.17 per share, in the same quarter of 2025.

Revenue reached $12.7 million, against $0.9 million a year earlier. Nearly all of it was $12.3 million of previously deferred collaboration revenue, recognized after its partner said it would not exercise an option on a specified target.

The Swiss biotech develops gene-based medicines using CRISPR/Cas9 editing across four franchises: hemoglobinopathies, in vivo editing, CAR-T cell therapy and regenerative medicine. It co-develops and co-commercializes CASGEVY, the first approved CRISPR-based therapy, for sickle cell disease and transfusion-dependent Beta thalassemia.

R&D Climbs 22% While CASGEVY Revenue Share Trims Collaboration Costs

Research and development expense rose to $71.9 million from $58.9 million, mainly on higher external program spending and license fees. Acquired in-process Research and Development added $11.7 million, almost all a milestone under the Sirius Therapeutics siRNA agreement. General and administrative expense was $17.9 million, versus $16.9 million.

Collaboration expense, net, declined to $41.3 million from $57.1 million, which the company attributed to a larger share of CASGEVY revenue. Total operating expenses were $142.7 million, up from $132.9 million, leaving an operating loss of $130.0 million compared with $132.1 million.

Other income, net, was $18.7 million, down from $26.2 million, on interest expense on the convertible notes and a change in Fair Value of Equity securities. For the nine months, the net loss was $325.5 million versus about $451.0 million (calculated), or $3.38 per share against $5.12.

CTX310 Durability Data and a Broad Clinical Pipeline Frame the Spending

In August 2026, the company presented one-year Phase 1a data for CTX310, its in vivo ANGPTL3 program, at a European cardiology congress, with simultaneous publication in a major medical journal. At the highest dose, mean reductions were 79% for ANGPTL3, 48% for triglycerides and 53% for LDL cholesterol, with no treatment-related serious adverse events. The program holds two U.S. regenerative medicine advanced therapy designations.

CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency are in Phase 1 trials. The long-acting Factor XI siRNA candidate CTX611 is in Phase 2, and a knee arthroplasty trial recently completed enrollment.

$2.28 Billion Cash Position Funds Operations for at Least 24 Months

The company held $2,276.6 million in cash, cash equivalents and marketable securities at Sep 30, 2026. Net cash used in Operating Activities was $282.1 million for the nine months, versus $252.5 million a year earlier. Management expects current resources to cover needs for at least 24 months, excluding partner proceeds.

Debt consists of $600.0 million of convertible senior notes due March 1, 2031, with an initial conversion price of about $76.56 per share. The filing gives no dated readout, so further clinical updates across the in vivo, CAR-T and siRNA programs are the next items to follow.